ANS-014004 is under development for the treatment of solid tumor and non small cell lung cancer (NSCLC). The therapeutic candidate is administered through oral route as tablet formulation. It acts by ...

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Mohali, is inviting applications for its prestigious PhD program in Biotechnology, commencing in January 2025, with research ...

Anbio Biotechnology seeks IPO funding to expand in the IVD market. Discover why NNNN stock’s potential is tempered by ...

Achieving biotech sovereignty will reduce dependency on foreign nations for critical products and technologies, ensuring ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Anbio Biotechnology filed for a 1.6 million-share initial public offering with the Securities and Exchange Commission. The company said Tuesday it expects the IPO to price between $5 and $6 per share, ...

The year 2025 will witness India assuming critical role in the global biotechnology revolution, and the first Bio-E3 policy ...

Biotechnology, a transformative field at the crossroads of science and technology, continues to revolutionize industries ...

University of York spin-out, Cizzle Biotechnology, has announced that it has appointed a new chief scientific officer (CSO).

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...